


COVID-19 Vaccine Development at Novavax Inc.

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax' patented **XXX**[™] to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease.

Novavax's journey from publishing its sequence in January 2020 to conducting clinical trials across countries speaks of its expansive business plan. Novavax has entered into an agreement with Govt. of **XXX** for delivery of approximately **XXX** doses.

Manufacturing and Distribution

In **XXX**, Novavax has licensed its NVX-CoV2373 technology to **XXX** with no upfront milestone or technology transfer payments. In March 2021, **XXX** on COVID-19, has given a nod to **XXX** for conducting **XXX** Phase 2/3 clinical trials on NVX-CoV2373. This strategic partnership shall enable Novavax and **XXX** to jointly deliver about **XX** doses to the **XXX**.



Source:

In **XXX**, Novavax entered into a **XXX** license agreement with **XXX** on February 24, 2021. This agreement grants **XXX** an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in **XXX**. It is anticipated that **XXX** has the capacity to manufacture about **XXX** doses of the vaccine product per year. In **XXX**, Novavax has extended its partnership with **XXX** to supply **XXX** doses of NVX-CoV2373.


As per **XXX**, Novavax plans to submit **regulatory dossier XXX**. For development of NVX-CoV2373, the company has secured cumulative funding of over **XXX** through **XXX** till date.

In XXX, Novavax has reached XXX for plans to produce NVX-CoV2373 at the XXXX. In addition to XXXX, rolling submission reviews have been initiated with XXX.

As per XXX, In November 2020 XXX granted NVX-CoV2373 XXX, and further Novavax plans to file a XXX. The company also plans to file submissions for XXX and expect to complete XXX.

Novavax Vaccine Development Status across various geographies

Studies were conducted on two dose strengths – XXX. The XXX was generally well tolerated and chosen as the candidate for global clinical trials. NVX-CoV2373 is currently under evaluation in two pivotal Phase 3 trials – in XXX (with overall efficacy of XXX) and the XXX trial in the XXX commenced in December 2020. Further, investigations are ongoing in XXX that began in August 2020: a Phase 2b trial in XXX that demonstrated XXX efficacy against a newly XXX variant XXX, and a Phase 1/2 continuation in the XXX.



Source: KPIED Research

Novavax Vaccine Technology: XXX™-adjuvanted nanoparticle- recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS).

Advantage of Technology: XXX.

Storage Conditions: XXX

Dosage and Dosage form: XXX

Mode of administration: XXX